Updated 14:15 GMT, 21 Nov 2026 SPX 6,910.39 -3.70% NDX 25,028.98 -5.61% VIX 35.89 +26.20% GOLD 3,515.40 -4.62% CL 83.98 +0.93% BTC 60,166.89 +2.33%
NAS100 25,029 −5.61% S&P 6,910 −3.70% GOLD $3,515 −4.62% BTC $60,167 +2.33% VIX 35.89 +26.20% latest tape · as of 14:15 UTC
The Screen · Healthcare · Biotechnology

Zenas BioPharma, Inc. logoZenas BioPharma, Inc.

ZBIO · Nasdaq · USD · Market cap $1.7B · 167 employees

Zenas BioPharma, Inc., a clinical-stage biopharma company, engages in the development and commercialization of transformative immunology-based therapies.

FAIL · Does not pass the screen
23.85 USD

Price as of 20 Nov 2026Daily close, not a live quote

Screened 2026-11-20 · the tape above runs as of 14:15 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed

Key facts today

  • Price23.85 USD at the 20 Nov 2026 close
  • Our value readUndervalued vs our fair value, as of 20 Nov 2026
  • Our regime readAccumulation, as of 15 Nov 2026
  • Ethical screenDoes not pass
  • OptionsOpen interest leans heavily to calls (put/call 0.00)
  • Last reviewed20 Nov 2026 (1 day ago)
  • Release timesRelease and earnings times on your chart: Event Guard Mentor

A summary of the dated readings below, not a live quote and not advice.

PRICE · ONE YEAR

Our fair-value range: $32.00 to $50.08, base estimate $46.50 (screen dated 2026-11-20).

Current read
Accumulation ?
Undervalued · screened 2026-11-20
  • Trend Accumulation
  • Insiders no filings inside 60 days, left as found
  • Positioning no disclosures inside 60 days, left as found
  • Options put/call open interest 0.00, read 2026-11-20
  • Ethical does not pass the values gate
Price23.85 USD
Fair value46.50
Ethical score70.0/100
Value readUndervaluedas of 20 Nov 2026
Our investment reviews on this name
2026-11-01Read Accumulation28.39-16.0% to today Markdown gives way to Accumulation after a 13% slide in 4 weeks
2026-10-02Read Markdown32.55-26.7% to today ✓Accumulation gives way to Markdown with volume flow in agreement
2026-09-18Read Accumulation32.32-26.2% to today Markup gives way to Accumulation first Accumulation read since July
2026-08-19Read Markup31.29-23.8% to today Accumulation gives way to Markup after a 58% rise in 7 weeks

Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.

The full research record, in depth, below
The Label · The Season, Not the Day

This name holds its accumulation label.

Zenas BioPharma, Inc. holds its Accumulation at $23.85. Consolidating, no directional conviction, held for 68 days.

As held on the ledger · 2026-11-20
PhaseAccumulation
Quantitative stateConsolidating, no directional conviction, held for 68 days
Price at the screen$23.85
ValuationN/A trailing · -5.20 forward price to earnings
Values screenFAIL · score 70.0
Beta-0.86
The Workings

Five Screens: ZBIO's Results

FAIL. Interest-bearing securities

TestFigureLimitStatus
Business activity Permissible Permissible core business Pass
Debt load 0.35% Below 33% Pass
Interest-bearing cash 60.62% Below 33% Fail
Receivables 28.84% Below 49% Pass
Revenue purity 100.00% Below 5% Fail

Definitions, sources and threshold rules: ticker values-screen methodology.

The Ethical Read

Why It Falls Short, in Plain English

Zenas BioPharma,'s business is fine, but its cash and interest-bearing securities are about 61% of its assets, well over the ~33% line, so it does not pass on the financial screens.

Read as at 20 Nov 2026. It updates when the underlying figures move, and past reads are kept below. How we screen.

Follow this verdict

Get an email when ZBIO's ethical verdict changes

Today ZBIO does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.

Free, no account needed. Every email has a link to stop.

What the Numbers Say It Is Worth

The Fair Value Range

Our analysis reads Undervalued to fair value, as of 20 Nov 2026: it trades at roughly a 49% discount to our $46.50 fair value.

Method.

32.00Conservative46.50Base case50.08Growth case 23.85Price

USD, 2026-11-20 screen. A 48.7% under base.

The Street's Range
32.00Street low 46.50Street average 59.00Street high 23.85Price

Street: 8 covering, consensus Strong Buy. Average target +95%.

Chart
The Business, in Plain Words

Biotech bet with no financials to judge

Picture a lab team betting everything on one antibody still in early trials. Zenas BioPharma offers exactly that, a clinical stage immunology programme with zero revenue and no profit margin to show for it. Analysts like the story enough for a strong buy call and a forty four dollar median target, yet our screen returns insufficient data and no opportunity rating at all.

The reported numbers underline the gap. Forward earnings sit at minus thirteen times, return on equity runs at minus one hundred thirty seven percent, and the company has yet to clear the basic financial ratios we check. Without those anchors any margin of safety calculation remains guesswork even when the share price sits well below our internal fair value line.

Risk here is therefore unquantifiable on standard metrics. Currency, dilution and trial failure sit on top of the ethical data shortfall. We pass until the figures arrive. Analysis, not advice.

The fundamentals · plain-English read
Forward P/E-5.2x
EPS, trailing-10.08
EPS, forward-4.82
Profit margin0.0%currently unprofitable
Return on equity-265.1%not currently earning a positive return on equity
FCF yield-14.76%
Debt to equity1.42a meaningful debt load worth watching
Current ratio9.42comfortably covers its short-term bills
Beta-0.86barely tracks the market's swings
Short interest, float0.24%
52-week range13.50 - 44.60
Market cap$1.7B
Employees167

ZBIO-specific watchpoints · The things to watch: it's a small-cap, so the share price can swing harder than the market; as a biotechnology name, trial and regulatory outcomes can move it sharply either way.

Metric definitions and interpretation rules: ticker-page methodology.

The Dated Journal · Newest First, Never Edited

Every Entry, As Written

2026-11-20 Accumulation $25.04 -5.2% Entry 13
2026-11-19 Accumulation $26.42 -7.9% Entry 12
2026-11-12 Accumulation $28.70 +0.8% Entry 11
2026-11-05 Accumulation $28.46 +0.2% Entry 10

Earnings landed in this window.

2026-11-01 Accumulation · changed $28.39 +0.6% Entry 9

The framework has shifted from markdown to accumulation since the last review.

2026-10-25 Markdown $28.23 +13.6% Entry 8
2026-10-18 Markdown $24.86 -23.6% Entry 7
2026-10-02 Markdown · changed $32.55 +0.7% Entry 6

The framework has shifted from accumulation to markdown since the last review.

2026-09-18 Accumulation · changed $32.32 +3.3% Entry 5

The framework has shifted from markup to accumulation since the last review.

2026-08-19 Markup · changed $31.29 +58.0% Entry 4

The framework has shifted from accumulation to markup since the last review. Ethical screening: FAIL.

Written on its date, before the outcome; never pruned.

Latest News · What the Market Is Reading on ZBIO

Headlines from third-party outlets, linked for reference: not our reporting, not advice.

Related Securities · Others in ZBIO's Space

Screened names in the same industry · explore each on its own page.

What Holding Actually Paid · Price Plus Dividends
If $1,000 had been placed · historical, not a promise
PeriodPrice thenPrice returnDivs per share$1,000 becameTotal return
1 month $20.40 -12.2% · $878 -12.2%
2 months $20.44 -12.4% · $876 -12.4%
3 months $24.50 -26.9% · $731 -26.9%
6 months $40.21 -55.5% · $445 -55.5%
1 year $11.94 +50.0% · $1,500 +50.0%

Historical returns from market close data. Past performance does not guarantee future results.

The Ledger's Promise

This entry now belongs to the ledger. Whatever ZBIO does next, these words stay.

Zenas BioPharma, Inc. · ZBIO · Accumulation · $23.85
Recorded 2026-11-20 · before the outcome · scored mechanically

Membership

Thirteen thousand names carry this page. One desk keeps them honest.

Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.

Join the desk

Screening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.

Get our weekly market brief free.